This meta-analysis compared low-dose rivaroxaban with standard antithrombotic therapy across the spectrum of coronary artery disease. It pooled five randomised controlled trials, with 37 709 patients, found through MEDLINE, EMBASE, Cochrane and meeting proceedings. All-cause mortality was lower with rivaroxaban (incidence rate ratio [IRR] 0.83, 95% CI 0.70-0.98), driven by cardiovascular mortality (IRR 0.82). Myocardial infarction (IRR 0.88) and stroke (IRR 0.71) were also reduced. Ischaemic stroke was also lower (IRR 0.60), with no offsetting rise in haemorrhagic stroke. Major bleeding rose (IRR 1.46), though its interval of 0.99-2.17 included no effect, and fatal bleeding did not rise.
Why it is interesting: The pooled trials show a fall in deaths, not only in heart attacks and strokes. That fall in deaths came with more major bleeding, though fatal bleeding did not rise.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.